0
Zymeworks Inc. Banner Image

Zymeworks Inc.

  • Ticker ZYME
    Exchange NYSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Zymeworks Inc. Logo Image
  • 201-500 Employees
  • Based in Vancouver, British Columbia
Zymeworks (NYSE:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel AzymetricMore™ bispecific antibody currently in a registration-enabling clinical trial for refractory HER2+ biliary tract cancer as well as several Phase 2 clinical trials for HER2+ gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
Zymeworks Inc.

Most Recent Responsibility Report

Zymeworks Inc.
MOST RECENT 2022 ESG Report

Report Locked. Zymeworks Inc. has reached its limit for free report views.

Our service enables potential investors to review the most recent and archived Zymeworks Inc. Sustainability Report, Zymeworks Inc. Corporate Social Responsibility Report, Zymeworks Inc. CSR Report, Zymeworks Inc. Corporate Responsibility, Zymeworks Inc. CR Report, Zymeworks Inc. Citizenship Report, Zymeworks Inc. ESG Report, and Zymeworks Inc. Environmental Report online.
Zymeworks Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!